Avalo Therapeutics to join Russell 2000, 3000 indexes (AVTX:NASDAQ)
Avalo Therapeutics (AVTX) joins the Russell 2000 & Russell 3000 effective June 26, 2026.
YayaNews contributes financial news and market context through the YayaNews editorial workflow.
Avalo Therapeutics (AVTX) joins the Russell 2000 & Russell 3000 effective June 26, 2026.
Avalo Therapeutics to join Russell 2000, 3000 indexes (AVTX:NASDAQ) | Seeking Alpha
Copy Link
Save
Play
(
<1min
)
Comments
Avalo Therapeutics (
AVTX
) is set to join the small-cap Russell 2000 Index and the broad-market Russell 3000 Index.
TheÂ
addition
is effective after the close of U.S. equity markets on June 26, 2026.
More on Avalo Therapeutics
Avalo Therapeutics: Sell-Off Could Continue If Overall Market Deteriorates Further
Avalo Therapeutics: Abdakibart Delivers Breakout Phase 2 HS Data
Avalo Therapeutics GAAP EPS of -$0.98 beats by $0.05
Avalo Therapeutics prices $375M public offering; shares jump
Seeking Alphaâs Quant Rating on Avalo Therapeutics
To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Search field
Entering text into the input field will update the search result below
Entering text into the input field will update the search result below
Recommended For You
More
Trending News
See More
»
Original YayaNews editorial coverage, published for informational purposes.
This article is sourced from Seeking Alpha. It is for informational purposes only and does not constitute investment advice.
Topics & Symbols
Continue Reading
Related Reading
Bowman Consulting Non-GAAP EPS of $0.62 beats by $0.16, revenue of $146.12M beats by $0.32M (NASDAQ:BWMN)
Bowman Consulting press release (BWMN): Q2 Non-GAAP EPS of $0.62 beats by $0.16. Revenue of $146.12M (+19.7% Y/Y) beats by $0.32M. Full Year 2026 Guidance Bowma
Oruka Therapeutics GAAP EPS of -$0.55 misses by $0.01 (NASDAQ:ORKA)
Oruka Therapeutics press release (ORKA): Q2 GAAP EPS of -$0.55 misses by $0.01. As of June 30, 2026, Oruka had cash, cash equivalents and marketable securities
Powerfleet Raises FY2027 Guidance: South Africa Contract Drives Annualized Revenue to $495M with 27% EBITDA Margin
Powerfleet projects FY2027 Q4 annualized revenue of $495 million and adjusted EBITDA margin of 27%, driven by a major South Africa contract. The guidance upgrade signals strong growth and market confidence.
Berkshire Earnings Beat, GameStop Adjusts Financing; Midday Market Roundup
Berkshire Hathaway's quarterly operating profit beat expectations and cash reserves hit a record high, while GameStop modified its convertible notes terms. Tech stocks were mixed and energy strengthened, with markets eyeing inflation data and Fed speeches.
